The promoter methylation TAC1, HOXA17, and SOX17 in sputum obtained from a prospective cohort of 150 NSCLC patients and 60 controls showed sensitivity and specificity of 98% and 71%, respectively [33]. The gene discussed is SOX17; the disease is non-small cell lung carcinoma.